Safety of Dupilumab Therapy for Atopic Dermatitis during Pregnancy: A Systematic Review and Meta-analysis
DOI:
https://doi.org/10.2340/actadv.v105.41307Keywords:
atopic dermatitis, biological therapy, pregnancy, spontaneous abortion, congenital abnormalitiesAbstract
Atopic dermatitis (AD) is the most common skin condition among pregnant women. However, there is limited information on the safety of biologicals during pregnancy. A systematic review and meta-analysis was conducted following the PRISMA guidelines to evaluate the effects of exposure to biologicals during pregnancy and/or preconception in women with AD, and to
estimate the pooled prevalence of spontaneous abortions and congenital malformations in their newborns. MEDLINE, Embase, Scopus, and Web of Science to 31 May 2024 were searched to identify randomized controlled trials and non-randomized studies. To test the robustness of our findings, sensitivity analyses were performed. Fifteen observational studies involving 115 pregnant women with a mean age of 33.46 years (standard deviation [SD] 3.02 were included). All studies evaluated dupilumab. The mean duration of exposure to dupilumab during pregnancy was 27.52 weeks (SD 11.16). The weighted prevalence of spontaneous abortions was 18.9% (95% confidence interval 5.3 to 38.2). There were no reports of congenital malformations. The sensitivity analyses showed no significant differences in weighted prevalences. In conclusion, the current scientific evidence suggests that dupilumab is probably safe during pregnancy and preconception in women with AD, with no significant increase in the risk of miscarriage or congenital malformations compared to the general population. However, the results of this review are inconclusive due to the limited number of large, well-designed clinical studies.
Downloads
References
Akuffo-Addo E, Nicholas MN, Lansang P. Reported Pregnancy Outcomes in Women With Severe Atopic Dermatitis Treated With Dupilumab: A Systematic Review. J Cutan Med Surg 2023; 27: 177-178.
https://doi.org/10.1177/12034754231152223 DOI: https://doi.org/10.1177/12034754231152223
Ambros-Rudolph CM, Müllegger RR, Vaughan-Jones SA, Kerl H, Black MM. The specific dermatoses of pregnancy revisited and reclassified: results of a retrospective two-center study on 505 pregnant patients. J Am Acad Dermatol 2006; 54: 395-404.
https://doi.org/10.1016/j.jaad.2005.12.012 DOI: https://doi.org/10.1016/j.jaad.2005.12.012
Horiuchi Y. Th2 shift in pregnancy and labor: An immunological perspective to elucidate the pathogenesis onset of atopy. Am J Reprod Immunol 2023; 90: e13716.
https://doi.org/10.1111/aji.13716 DOI: https://doi.org/10.1111/aji.13716
Vestergaard C, Wollenberg A, Barbarot S, Christen-Zaech S, Deleuran M, Spuls P, et al. Euro-pean task force on atopic dermatitis position paper: treatment of parental atopic dermati-tis during preconception, pregnancy and lactation period. J Eur Acad Dermatol Vene-reol 2019; 33: 1644-1659.
https://doi.org/10.1111/jdv.15709 DOI: https://doi.org/10.1111/jdv.15709
Avgil M, Ornoy A. Herpes simplex virus and Epstein-Barr virus infections in pregnancy: con-sequences of neonatal or intrauterine infection. Reprod Toxicol 2006; 21: 436-445.
https://doi.org/10.1016/j.reprotox.2004.11.014 DOI: https://doi.org/10.1016/j.reprotox.2004.11.014
De Caux D, Mariappa G, Perera G, Girling J. Prescribing for pregnancy: Chronic skin diseases. Drug Ther Bull 2023; 61: 55-60.
https://doi.org/10.1136/dtb.2022.000036 DOI: https://doi.org/10.1136/dtb.2022.000036
Wollenberg A, Christen-Zäch S, Taieb A, Paul C, Thyssen JP, de Bruin-Weller M, et al. ET-FAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol 2020; 34: 2717-2744.
https://doi.org/10.1111/jdv.16892 DOI: https://doi.org/10.1111/jdv.16892
Pfaller B, José Yepes-Nuñez J, Agache I, Akdis CA, Alsalamah M, Bavbek S, et al. Biologi-cals in atopic disease in pregnancy: An EAACI position paper. Allergy 2021; 76: 71-89.
https://doi.org/10.1111/all.14282 DOI: https://doi.org/10.1111/all.14282
Wollenberg A, Kinberger M, Arents B, Aszodi N, Avila Valle G, Barbarot S, et al. European guideline (EuroGuiDerm) on atopic eczema - part II: non-systemic treatments and treatment recommendations for special AE patient populations. J Eur Acad Dermatol Venereol 2022; 36: 1904-1926.
https://doi.org/10.1111/jdv.18429 DOI: https://doi.org/10.1111/jdv.18429
Pfaller B, Bendien S, Ditisheim A, Eiwegger T. Management of allergic diseases in pregnancy. Allergy 2022; 77: 798-811.
https://doi.org/10.1111/all.15063 DOI: https://doi.org/10.1111/all.15063
Escolà H, Figueras-Nart I, Bonfill-Orti M, Coll Puigserver N, Martin-Santiago A, Rodríguez Serna M, et al. Dupilumab for atopic dermatitis during pregnancy and breastfeeding: Clinical experience in 13 patients. J Eur Acad Dermatol Venereol 2023; 37: e1156-1160.
https://doi.org/10.1111/jdv.19165 DOI: https://doi.org/10.1111/jdv.19165
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372: n71.
https://doi.org/10.1136/bmj.n71 DOI: https://doi.org/10.1136/bmj.n71
Moher D, Liberati A, Tetzlaff J, Altman DG, Altman D, Antes G, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6: e1000097.
https://doi.org/10.1371/journal.pmed.1000097 DOI: https://doi.org/10.1371/journal.pmed.1000097
Sterne JAC, Higgins JPT, Elbers RG, Reeves BC, and the development group for ROBINS-I. Risk Of Bias In Non-randomized Studies of Interventions (ROBINS-I): detailed guid-ance, updated 12 October 2016. https://www.riskofbias.info/. Accessed 4 May 2024.
Sampayo-Cordero M, Miguel-Huguet B, Malfettone A, Pérez-García JM, Llombart-Cussac A, Cortés J, et al. The Value of Case Reports in Systematic Reviews from Rare Diseases. The Example of Enzyme Replacement Therapy (ERT) in Patients with Mucopolysac-charidosis Type II (MPS-II). Int J Environ Res Public Health 2020; 17: 6590.
https://doi.org/10.3390/ijerph17186590 DOI: https://doi.org/10.3390/ijerph17186590
Sampayo-Cordero M, Miguel-Huguet B, Pardo-Mateos A, Moltó-Abad M, Muñoz-Delgado C, Pérez-López J. Agreement between the results of meta-analyses from case reports and from clinical studies regarding the efficacy of laronidase therapy in patients with mu-copolysaccharidosis type I who initiated enzyme replacement therapy in adult age: An example of case reports meta-analyses as an useful tool for evidence-based medicine in rare diseases. Mol Genet Metab 2018; 123: 69-75.
https://doi.org/10.1016/j.ymgme.2018.01.002 DOI: https://doi.org/10.1016/j.ymgme.2018.01.002
European Medicines Agency (EMA) Committee for Medicinal Products for Human Use. (CHMP) [Internet]. Dupixent Assessment Report July 2017. 2017. https://www.ema.europa.eu/en/documents/assessment-report/dupixent-epar-public-assessment-report_en.pdf. Accessed 5 Dec 2023.
Mian M, Dunlap R, Simpson E. Dupilumab for the treatment of severe atopic dermatitis in a pregnant patient: A case report. JAAD Case Rep 2020; 6: 1051-1052.
https://doi.org/10.1016/j.jdcr.2020.08.001 DOI: https://doi.org/10.1016/j.jdcr.2020.08.001
Kage P, Simon JC, Treudler R. A case of atopic eczema treated safely with dupilumab during pregnancy and lactation. J Eur Acad Dermatol Venereol 2020; 34: e256-257.
https://doi.org/10.1111/jdv.16235 DOI: https://doi.org/10.1111/jdv.16235
Kage P, Simon J-C, Treudler R. Case of atopic eczema treated with dupilumab throughout con-ception, pregnancy, and lactation. J Dermatol 2021; 48: E484-485.
https://doi.org/10.1111/1346-8138.16033 DOI: https://doi.org/10.1111/1346-8138.16033
Lobo Y, Lee RC, Spelman L. Atopic Dermatitis Treated Safely with Dupilumab during Preg-nancy: A Case Report and Review of the Literature. Case Rep Dermatol 2021; 13: 248-256.
https://doi.org/10.1159/000515246 DOI: https://doi.org/10.1159/000515246
Gracia-Darder I, Pons De Ves J, Reyero Cortina M, Martín-Santiago A. Patient with atopic dermatitis, hyper IgE syndrome and ulcerative colitis, treated successfully with dupi-lumab during pregnancy. Dermatol Ther 2022; 35: e15237.
https://doi.org/10.1111/dth.15237 DOI: https://doi.org/10.1111/dth.15237
Costley M, Murphy B. Severe atopic dermatitis treated successfully with dupilumab throughout pregnancy. Clin Exp Dermatol 2022; 47: 960-961.
https://doi.org/10.1111/ced.15049 DOI: https://doi.org/10.1111/ced.15049
Khamisy-Farah R, Damiani G, Kong JD, Wu J, Bragazzi NL. Safety profile of Dupilumab dur-ing pregnancy: a data mining and disproportionality analysis of over 37,000 reports from the WHO individual case safety reporting database (VigiBaseTM). Eur Rev Med Pharmacol Sci 2021; 25: 5448-5451.
Akhtar NH, Khosravi-Hafshejani T, Akhtar D, Dhadwal G, Kanani A. The use of dupilumab in severe atopic dermatitis during pregnancy: a case report. Allergy Asthma Clin Immu-nol 2022; 18: 9.
https://doi.org/10.1186/s13223-022-00650-w DOI: https://doi.org/10.1186/s13223-022-00650-w
Kojanova M, Tanczosova M, Strosova D, Cetkovska P, Fialova J, Dolezal T, et al. Dupilumab for the treatment of atopic dermatitis: real-world data from the Czech Republic BI-OREP registry. J Dermatolog Treat 2022; 33: 2578-2586.
https://doi.org/10.1080/09546634.2022.2043545 DOI: https://doi.org/10.1080/09546634.2022.2043545
Avallone G, Cavallo F, Tancredi A, Maronese CA, Bertello M, Fraghì A, et al. Association between maternal dupilumab exposure and pregnancy outcomes in patients with mod-erate-to-severe atopic dermatitis: A nationwide retrospective cohort study. J Eur Acad Dermatol Venereol 2024.
https://doi.org/10.1111/jdv.19794 DOI: https://doi.org/10.1111/jdv.19794
Hong N, Park SY, Kook HD, Lee DH, Jung HJ, Park MY, et al. Atopic dermatitis treated safe-ly with dupilumab during pregnancy and lactation: A case series of four patients. Aus-tralas J Dermatol 2024; 65: e100-e103.
https://doi.org/10.1111/ajd.14255 DOI: https://doi.org/10.1111/ajd.14255
Di Lernia V, Peccerillo F. Long-Term Follow-Up of Dupilumab Treatment During Conception, Pregnancy and Lactation. Indian J Dermatol 2024; 69: 193-195.
https://doi.org/10.4103/ijd.ijd_447_23 DOI: https://doi.org/10.4103/ijd.ijd_447_23
Alvarenga JM, Maria Lé A, Torres T. Dupilumab for Atopic Dermatitis During Pregnancy and Breastfeeding: A Case Report. Actas Dermosifiliogr 2023.
https://doi.org/10.1016/j.ad.2023.10.005 DOI: https://doi.org/10.1016/j.ad.2023.10.005
Carnovale C, Parisi F, Battini V, Zavatta A, Cheli S, Cattaneo D, et al. The use of biological agents in pregnant women affected by autoimmune disorders: Why we need more re-search of this neglected area. Pharmacol Res 2021; 171: 105786.
https://doi.org/10.1016/j.phrs.2021.105786 DOI: https://doi.org/10.1016/j.phrs.2021.105786
Flood KS, Porter ML, Kimball AB. Use of biologics in pregnancy: limitations stemming from clinical trials and registry experience. J Eur Acad Dermatol Venereol 2019; 33: e276-277.
https://doi.org/10.1111/jdv.15552 DOI: https://doi.org/10.1111/jdv.15552
Lambert JLW, Segaert S, Ghislain PD, Hillary T, Nikkels A, Willaert F, et al. Practical recom-mendations for systemic treatment in psoriasis according to age, pregnancy, metabolic syndrome, mental health, psoriasis subtype and treatment history (BETA-PSO: Bel-gian Evidence-based Treatment Advice in Psoriasis; part 1). J Eur Acad Dermatol Ve-nereol 2020; 34: 1654-1665.
https://doi.org/10.1111/jdv.16684 DOI: https://doi.org/10.1111/jdv.16684
List of Pregnancy Exposure Registries. https://www.fda.gov/consumers/pregnancy-exposure-registries/list-pregnancy-exposure-registries. Accessed 30 Mar 2024.
MotherToBaby. https://mothertobaby.org/ongoing-study/. Accessed 31 Mar 2024.
L. Ramos C, Namazy J. Monoclonal Antibodies (Biologics) for Allergic Rhinitis, Asthma, and Atopic Dermatitis During Pregnancy and Lactation. Immunol Allergy Clin North Am 2023; 43: 187-197.
https://doi.org/10.1016/j.iac.2022.07.001 DOI: https://doi.org/10.1016/j.iac.2022.07.001
ClinicalTrial.gov. Post-Authorization Safety Study to Monitor Pregnancy and Infant Outcomes Following Administration of Dupilumab During Planned or Unexpected Pregnancy in North America 2018. https://clinicaltrials.gov/study/NCT04173442. Accessed 1 Apr 2024.
ClinicalTrial.gov. Dupilumab and Pregnancy Outcomes: A Retrospective Cohort Study Using Administrative Healthcare Databases (Dupi PODS) 2019. https://clinicaltrials.gov/study/NCT03936335. Accessed 1 Apr 2024.
Namazy J, Cabana MD, Scheuerle AE, Thorp JM, Chen H, Carrigan G, et al. The Xolair Preg-nancy Registry (EXPECT): the safety of omalizumab use during pregnancy. J Allergy Clin Immunol 2015; 135: 407-412.
https://doi.org/10.1016/j.jaci.2014.08.025 DOI: https://doi.org/10.1016/j.jaci.2014.08.025
Blauvelt A, Guttman-Yassky E, Paller AS, Simpson EL, Cork MJ, Weisman J, et al. Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE). Am J Clin Dermatol 2022; 23: 365-383.
https://doi.org/10.1007/s40257-022-00683-2 DOI: https://doi.org/10.1007/s40257-022-00683-2
Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concom-itant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, dou-ble-blinded, placebo-controlled, phase 3 trial. Lancet 2017; 389: 2287-2303.
https://doi.org/10.1016/S0140-6736(17)31191-1 DOI: https://doi.org/10.1016/S0140-6736(17)31191-1
Simpson EL, Paller AS, Siegfried EC, Boguniewicz M, Sher L, Gooderham MJ, et al. Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atop-ic Dermatitis: A Phase 3 Randomized Clinical Trial. JAMA Dermatol 2020; 156: 44-56.
https://doi.org/10.1001/jamadermatol.2019.3336 DOI: https://doi.org/10.1001/jamadermatol.2019.3336
de Bruin-Weller M, Thaçi D, Smith CH, Reich K, Cork MJ, Radin A, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an in-adequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ). Br J Dermatol 2018; 178: 1083-1101.
https://doi.org/10.1111/bjd.16156 DOI: https://doi.org/10.1111/bjd.16156
Seeger JD, Lanza LL, West WA, Fernandez C, Rivero E. Pregnancy and pregnancy outcome among women with inflammatory skin diseases. Dermatology 2007; 214: 32-39.
https://doi.org/10.1159/000096910 DOI: https://doi.org/10.1159/000096910
Hamann CR, Egeberg A, Wollenberg A, Gislason G, Skov L, Thyssen JP. Pregnancy compli-cations, treatment characteristics and birth outcomes in women with atopic dermatitis in Denmark. J Eur Acad Dermatol Venereol 2019; 33: 577-587.
https://doi.org/10.1111/jdv.15256 DOI: https://doi.org/10.1111/jdv.15256
Schoder K, Zhu Y, Schneeweiss S, Merola JF, Savage TJ, Gibbs LR, et al. Use of systemic immunomodulating medications in pregnant women with atopic dermatitis: A nation-wide US study. J Am Acad Dermatol 2023; 89: 178-181.
https://doi.org/10.1016/j.jaad.2023.02.047 DOI: https://doi.org/10.1016/j.jaad.2023.02.047
Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. Clin Dev Immunol 2012; 2012: 985646.
https://doi.org/10.1155/2012/985646 DOI: https://doi.org/10.1155/2012/985646
Porter ML, Lockwood SJ, Kimball AB. Update on biologic safety for patients with psoriasis during pregnancy. Int J Womens Dermatol 2017; 3: 21-25.
https://doi.org/10.1016/j.ijwd.2016.12.003 DOI: https://doi.org/10.1016/j.ijwd.2016.12.003
Nybo Andersen AM, Wohlfahrt J, Christens P, Olsen J, Melbye M. Maternal age and fetal loss: population based register linkage study. BMJ 2000; 320: 1708-1712.
https://doi.org/10.1136/bmj.320.7251.1708 DOI: https://doi.org/10.1136/bmj.320.7251.1708
Ammon Avalos L, Galindo C, Li DK. A systematic review to calculate background miscarriage rates using life table analysis. Birth Defects Res A Clin Mol Teratol 2012; 94: 417-423.
https://doi.org/10.1002/bdra.23014 DOI: https://doi.org/10.1002/bdra.23014
Baldacci S, Gorini F, Santoro M, Pierini A, Minichilli F, Bianchi F. Environmental and individ-ual exposure and the risk of congenital anomalies: a review of recent epidemiological evidence. Epidemiol Prev 2018; 42: 1-34.
Sánchez-García V, Hernández-Quiles R, de-Miguel-Balsa E, Giménez-Richarte, Ramos-Rincón JM, Belinchón-Romero I. Exposure to biologic therapy before and during pregnancy in patients with psoriasis: Systematic review and meta-analysis. J Eur Acad Dermatol Venereol 2023; 37: 1971-1990.
https://doi.org/10.1111/jdv.19238 DOI: https://doi.org/10.1111/jdv.19238
European Medicines Agency. Dupixent CHMP assessment report on extension of marketing authorisation and an extension of indication variation. 2019. https://www.ema.europa.eu/en/documents/variation-report/dupixent-h-c-4390-x-0004-g-epar-assessment-report-extension_en.pdf. Accessed 30 Mar 2024.
Sanofi-aventis U.S. LLC. Dupixent (Dupilumab) injection. Prescribing information. 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761055lbl.pdf. Accessed 30 Mar 2024.
Piccinni MP, Maggi E, Romagnani S. Role of hormone-controlled T-cell cytokines in the maintenance of pregnancy. Biochem Soc Trans 2000; 28: 212-215.
https://doi.org/10.1042/bst0280212 DOI: https://doi.org/10.1042/bst0280212
Piccinni MP, Scaletti C, Maggi E, Romagnani S. Role of hormone-controlled Th1- and Th2-type cytokines in successful pregnancy. J Neuroimmunol 2000; 109: 30-33.
https://doi.org/10.1016/S0165-5728(00)00299-X DOI: https://doi.org/10.1016/S0165-5728(00)00299-X
Piccinni MP, Beloni L, Livi C, Maggi E, Scarselli G, Romagnani S. Defective production of both leukemia inhibitory factor and type 2 T-helper cytokines by decidual T cells in un-explained recurrent abortions. Nat Med 1998; 4: 1020-1024.
https://doi.org/10.1038/2006 DOI: https://doi.org/10.1038/2006
Murphy VE, Wang G, Namazy JA, Powell H, Gibson PG, Chambers C, et al. The risk of con-genital malformations, perinatal mortality and neonatal hospitalisation among pregnant women with asthma: a systematic review and meta-analysis. BJOG 2013; 120: 812-822.
https://doi.org/10.1111/1471-0528.12224 DOI: https://doi.org/10.1111/1471-0528.12224
Trønnes H, Wilcox AJ, Markestad T, Tollånes MC, Lie RT, Moster D. Associations of mater-nal atopic diseases with adverse pregnancy outcomes: a national cohort study. Paediatr Perinat Epidemiol 2014; 28: 489-497.
https://doi.org/10.1111/ppe.12154 DOI: https://doi.org/10.1111/ppe.12154
Kojima R, Yokomichi H, Akiyama Y, Ooka T, Miyake K, Horiuchi S, et al. Association be-tween preterm birth and maternal allergy considering IgE level. Pediatr Int 2021; 63: 1026-1032.
https://doi.org/10.1111/ped.14635 DOI: https://doi.org/10.1111/ped.14635
Pali-Schöll I, Namazy J, Jensen-Jarolim E. Allergic diseases and asthma in pregnancy, a sec-ondary publication. World Allergy Organ J 2017; 10: 10.
https://doi.org/10.1186/s40413-017-0141-8 DOI: https://doi.org/10.1186/s40413-017-0141-8
Mawhirt SL, Fonacier L. Atopic Dermatitis and Allergic Contact Dermatitis in Pregnancy. In: Namazy J, Schatz M, editors. Asthma, Allergic and Immunologic Diseases During Pregnancy. Springer, Cham; 2019: p. 101-21.
https://doi.org/10.1007/978-3-030-03395-8_7 DOI: https://doi.org/10.1007/978-3-030-03395-8_7
Bosma AL, Gerbens LAA, Middelkamp-Hup MA, Spuls PI. Paternal and maternal use of dupi-lumab in patients with atopic dermatitis: a case series. Clin Exp Dermatol 2021; 46: 1089-1092.
https://doi.org/10.1111/ced.14725 DOI: https://doi.org/10.1111/ced.14725
Napolitano M, Ruggiero A, Fontanella G, Fabbrocini G, Patruno C. New emergent therapies for atopic dermatitis: A review of safety profile with respect to female fertility, preg-nancy, and breastfeeding. Dermatol Ther 2021; 34: e14475.
https://doi.org/10.1111/dth.14475 DOI: https://doi.org/10.1111/dth.14475
Witzel SJ. Lactation and the use of biologic immunosuppressive medications. Breastfeed Med 2014; 9: 543-546.
https://doi.org/10.1089/bfm.2014.0107 DOI: https://doi.org/10.1089/bfm.2014.0107
Ingrasci G, Lipman ZM, Yosipovitch G. When topical therapy of atopic dermatitis fails: a guide for the clinician. Expert Rev Clin Immunol 2021; 17: 1245-1256.
https://doi.org/10.1080/1744666X.2021.2000390 DOI: https://doi.org/10.1080/1744666X.2021.2000390
Duricova D, Dvorakova E, Hradsky O, Mitrova K, Durilova M, Kozeluhova J, et al. Safety of anti-Tnf-Alpha therapy during pregnancy on long-Term outcome of exposed children: A controlled, multicenter observation. Inflamm Bowel Dis 2019; 25: 789-796.
https://doi.org/10.1093/ibd/izy294 DOI: https://doi.org/10.1093/ibd/izy294
European Medicines Agency. Adtralza (Tralokinumab). European Public Assessment Report. 2021. https://www.ema.europa.eu/en/medicines/human/EPAR/adtralza. Accessed 30 Mar 2024.
LEO Pharma Inc. Adtralza (Tralokinumab) injection. Product monograph. 2021. https://pdf.hres.ca/dpd_pm/00063207.PDF. Accessed 30 Mar 2024.
Nambiema A, Sembajwe G, Lam J, Woodruff T, Mandrioli D, Chartres N, et al. A Protocol for the Use of Case Reports/Studies and Case Series in Systematic Reviews for Clinical Toxicology. Front Med (Lausanne) 2021; 8: 708380.
https://doi.org/10.3389/fmed.2021.708380 DOI: https://doi.org/10.3389/fmed.2021.708380
Additional Files
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2025 Verónica Sánchez-García, Eva de-Miguel-Balsa, José-Manuel Ramos-Rincón, Isabel Belinchón-Romero
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
